Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for guidance on your individual care.
The American Diabetes Association publishes updated clinical practice guidelines every January — the Standards of Medical Care in Diabetes — representing the most comprehensive, evidence-based recommendations for Type 2 diabetes diagnosis, treatment, and monitoring available. Understanding what these standards say helps you know what your care team should be doing and what questions to ask if you’re not receiving guideline-concordant care.
Screening and Diagnosis
The ADA recommends diabetes screening for:
- All adults aged 45 and older, regardless of weight
- Adults of any age with BMI ≥ 25 (or ≥ 23 for Asian Americans) plus one additional risk factor (family history, physical inactivity, certain ethnicities, history of gestational diabetes, prediabetes, hypertension, or dyslipidemia)
- Repeat testing every 3 years if results are normal
Diagnosis requires one of: fasting glucose ≥ 126 mg/dL, A1C ≥ 6.5%, 2-hour OGTT ≥ 200 mg/dL, or random glucose ≥ 200 mg/dL with symptoms. Abnormal results should be confirmed with a repeat test on a separate day unless clearly symptomatic.
Glycemic Targets
The ADA’s glycemic targets for most non-pregnant adults with Type 2 diabetes:
| Measure | Target | Notes |
|---|---|---|
| A1C | < 7.0% | Less strict (<8%) for older adults, limited life expectancy, or high hypoglycemia risk |
| Fasting glucose | 80–130 mg/dL | Before meals |
| Post-meal glucose (2 hr) | < 180 mg/dL | Measured 2 hours after first bite |
| Time-in-range (CGM) | >70% between 70–180 mg/dL | Endorsed as a valid glycemic metric alongside A1C |
A more stringent A1C target (below 6.5%) may be appropriate for younger patients with short disease duration, no significant cardiovascular disease, and low hypoglycemia risk — if achievable without excessive treatment burden.
Pharmacologic Treatment: What the ADA Now Recommends
One of the most significant shifts in recent ADA guidelines is the move away from a purely glucose-centric approach. The current standards recommend choosing medications based not just on A1C, but on their cardiometabolic effects:
- Metformin remains the preferred initial medication for most people, combined with lifestyle intervention
- GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide, dulaglutide) are recommended for people with established cardiovascular disease, high CV risk, or those who would benefit from weight loss — regardless of baseline A1C
- SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) are recommended for people with heart failure or chronic kidney disease — regardless of A1C — due to organ-protective effects
- Combination therapy is appropriate at diagnosis when A1C is significantly above target (e.g., >9%)
The full ADA Standards are published annually in Diabetes Care and are freely accessible online.
Cardiovascular Risk Management
Given that cardiovascular disease is the leading cause of death in Type 2 diabetes, the ADA standards emphasize cardiovascular risk reduction as integral to diabetes care:
- Blood pressure target: below 130/80 mmHg for most people with diabetes; below 120/80 mmHg if tolerated for those with high CVD risk
- Lipids: statin therapy recommended for all adults with diabetes aged 40–75; high-intensity statins for those with CVD
- Aspirin: low-dose aspirin recommended only for adults with established CVD; not routinely recommended for primary prevention due to bleeding risk
- 10-year CVD risk assessment: the ADA recommends annual assessment using validated risk calculators
Complication Screening Schedule
The ADA recommends the following screening schedule for people with Type 2 diabetes:
| Complication | Screening Test | Frequency |
|---|---|---|
| Kidney disease | Urine albumin-to-creatinine ratio + eGFR | Annually |
| Eye disease (retinopathy) | Dilated eye exam | At diagnosis; then annually (or every 2 years if normal x2) |
| Neuropathy | Comprehensive foot exam including monofilament | Annually; foot inspection every visit |
| Cardiovascular disease | Blood pressure, lipid panel, 10-year CVD risk | Every visit (BP); annually (lipids, risk) |
| Mental health | Screening for depression, diabetes distress, anxiety | Annually or at significant changes in health status |
Diabetes Self-Management Education and Support (DSMES)
The ADA standards identify four critical times when DSMES is particularly valuable: at diagnosis, annually or when not meeting treatment goals, when complicating factors develop, and during transitions in care. DSMES is covered by Medicare and most private insurers. Working with a Certified Diabetes Care and Education Specialist (CDCES) has been shown to improve A1C, reduce hospitalizations, and improve quality of life.
Newer Additions: Social Determinants and Mental Health
Recent ADA standards have expanded beyond purely clinical metrics to address factors that profoundly affect diabetes outcomes. The guidelines now explicitly address:
- Food insecurity: providers should screen for food insecurity and connect patients with resources; food insecurity is strongly associated with poor glycemic control
- Diabetes distress: distinct from clinical depression, diabetes distress affects up to 45% of people with Type 2 diabetes and should be screened for annually
- Structural determinants of health: neighborhood, income, and access to care profoundly affect outcomes and should inform treatment planning
Related Reading
- How Is Type 2 Diabetes Managed? Targets, Treatments, and Daily Care
- Best Treatment Options for Type 2 Diabetes: Medications, Lifestyle, and Surgery
- Type 2 Diabetes Complications: What They Are and How to Prevent Them
- Continuous Glucose Monitors (CGMs) for Type 2 Diabetes
